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Abstract: The impacts of novel coronavirus disease-2019 (COVID-19) on human life continue to
be serious. To control the spread of COVID-19, the production of effective vaccines is likely to be
one of the best solutions. However, vaccination hesitancy may decrease individuals’ willingness
to get vaccinated. The Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-COVID19S) was
recently developed to help healthcare professionals and researchers better understand vaccination
acceptance. The present study examined whether DrVac-COVID19S is measurement invariant
across different subgroups (Taiwanese vs. mainland Chinese university students; males vs. females;
and health-related program majors vs. non-health-related program majors). Taiwanese (n = 761;
mean age = 25.51 years; standard deviation (SD) = 6.42; 63.5% females) and mainland Chinese uni-
versity students (n = 3145; mean age = 20.72 years; SD = 2.06; 50.2% females) were recruited using an
online survey between 5 January and 21 February 2021. Factor structure and measurement invariance
of the two DrVac-COVID19S scales (nine-item and 12-item) were tested using confirmatory factor
analysis (CFA). The findings indicated that the DrVac-COVID19S had a four-factor structure and was
measurement invariant across the subgroups. The DrVac-COVID19S’s four-factor structure was sup-
ported by the CFA results is a practical and valid instrument to quickly capture university students’
willingness to get COVID-19 vaccination. Moreover, the DrVac-COVID19S can be used to compare
university students’ underlying reasons to get COVID-19 vaccination among different subgroups.
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1. Introduction
Coronavirus disease 2019 (COVID-19) was identified as a worldwide pandemic in
early 2020. Consequently, individuals globally have had their everyday life activities
substantially impacted for over a year at the time of writing [1–4]. The impacts of COVID-
19 have been great given that individuals’ physical, psychological, and social health have
been jeopardized. This has been due to COVID-19′s impact both directly (e.g., the physical
discomfort or physical impairment due to the COVID-19 infection) and/or indirectly
(e.g., the policy of preventing COVID-19 infection such as lockdown that may impair
an individual’s physical or psychosocial health) [5–19]. Unfortunately, no country is
immune to the impacts of COVID-19 because many countries are still suffering from
continued waves of COVID-19 outbreaks [4,7,20]. Expectations for controlling COVID-19
transmissions rely heavily on the vaccines that have been produced. Through countrywide
vaccination programs, governments worldwide are likely to be able to control the COVID-
19 outbreaks and significantly curtail the negative impact of COVID-19 and resume in-
person global interactions.
Although governments and healthcare providers are pleased that effective COVID-19
vaccines have now been developed, an unresolved problem is the willingness of individuals
to have them [21,22]. More specifically, the uptake rate of COVID-19 vaccination will
influence whether global communities can be fully protected from COVID-19 and avoid
future outbreaks [23–25]. When a significant number of individuals get vaccinated, the
infection rate of COVID-19 can be controlled and will avoid further community outbreaks.
To date, more than 160 candidate vaccines have been tested to respond to the urgent need
for a COVID-19 vaccine [26–28]. Given that some of these have now shown to be effective
in clinical trials, the next step in effective COVID-19 vaccination is to maximize the uptake
rate of the effective vaccines. Therefore, information concerning individuals’ attitudes
and considerations to get vaccinated should be investigated to promote individuals and
communities to uptake COVID-19 vaccination.
The Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-COVID19S) appears
to be a good candidate instrument to assess individuals’ attitudes and considerations
in getting vaccinated against COVID-19. The DrVac-COVID19S was adapted from a
well-established instrument assessing influenza vaccination acceptance (i.e., Motors of
Influenza Vaccination Acceptance Scale; MoVac-Flu Scale) [29]. Therefore, the DrVac-
COVID19S shares the same cognitive model of empowerment (CME) as the MoVac-Flu
Scale in understanding different traits described in the CME [29,30]. The CME proposes
that empowerment is an intrinsic motivation that is determined by four cognitive traits
for individuals to perform purposeful behaviors, such as vaccination uptake. These four
cognitive traits are values (i.e., how an individual cares about the purpose of COVID-19
vaccination uptake), impacts (i.e., how an individual believes in the effects of COVID-19
vaccination uptake in preventing COVID-19 infection), knowledge (i.e., how an individual
has knowledge regarding the COVID-19 vaccination uptake), and autonomy (i.e., how
much an individual is confident and has control in getting COVID-19 vaccination if the
individual wants to). In other words, when the CME is applied to understand an individ-
ual’s attitudes and considerations in getting vaccinated against COVID-19, the individual’s
values, perceived impacts, knowledge, and autonomy are key traits for them to get vaccinated
against COVID-19.
The factor structure of the DrVac-COVID19S has been found to fit well with the CME
model among a mainland Chinese sample using the confirmatory factor analysis (CFA) [31].
In addition, two versions of the DrVac-COVID19S have been proposed: a nine-item DrVac-
COVID19S with all items positively worded and a 12-item DrVac-COVID19S with nine
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items positively worded and three items negatively worded. Both versions fit well with
the four-trait-factor structure in the CME model. Moreover, the 12-item DrVac-COVID19S
fitted well with the CME model when the wording effects were controlled for in the CFA
models [31]. However, aside from the aforementioned study, to the best of the present
authors’ knowledge, no other psychometric evidence for the DrVac-COVID19S has been
examined. Therefore, there is a need to further understand the psychometric properties of
the DrVac-COVID19S.
In order to provide additional psychometric evidence of the DrVac-COVID19S, the
present study examined the measurement invariance properties of the DrVac-COVID19S
across subsamples. Measurement invariance is an important property that identifies
whether the score difference of an instrument (e.g., the DrVac-COVID19S in the present
study) detects the true differences between subsamples or whether the differences are
due to various interpretations of the item descriptions in the instrument [32,33]. However,
given that the DrVac-COVID19S was developed recently, no information regarding the
measurement invariance of the DrVac-COVID19S has been reported. With knowledge of
the measurement invariance of the DrVac-COVID19S, researchers, healthcare providers,
and policymakers will have information to compare and evaluate the true differences in
the acceptance of COVID-19 vaccination between different subsamples. In this regard,
healthcare providers, researchers, and policymakers may use different findings between
subsamples (e.g., males vs. females) to assist them in taking the best approach to pro-
mote uptake of COVID-19 vaccination [34]. When information concerning measurement
invariance is not reported, it is not known whether the differences between subsamples
are real differences or interpretation differences [35]. Therefore, from the perspective of
psychometric testing, testing the measurement invariance of the DrVac-COVID19S across
different subsamples is both important and necessary.
Consequently, the aims of the present study were to (i) reconfirm the factor struc-
ture of the DrVac-COVID19S and (ii) examine the measurement invariance of the DrVac-
COVID19S across university students in three comparisons (i.e., Taiwan university students
vs. mainland Chinese university students; male university students vs. female university
students; university students majoring in a health-related program vs. university students
not majoring in a health-related program). The present study focused on university stu-
dents because they will be one of the last cohorts to get vaccinated because they are not
generally clinically vulnerable. Therefore, they may not be fully aware of the importance
of vaccination acceptance and/or will think they do not need to have a vaccine because
they are such a low-risk group. In this regard, it is important to test the DrVac-COVID19S
on this population to more deeply understand their attitudes and knowledge concerning
COVID-19 vaccination.
2. Methods
2.1. Participants and Procedure
Institutional review boards (IRBs) of the Kaohsiung Medical University Chung-Ho
Memorial Hospital (IRB ref: KMUHIRB-EXEMPT(I)-20200119) and the Jianxi Psychological
Consultant Association (IRB ref: JXSXL-2020-DE22) approved the study protocol before
data collection commenced. The study adopted a cross-sectional design, and all data
collection used snowball sampling (a type of convenience sampling). For collecting data
from Taiwanese university students, Google Forms was used to host an online survey, and
the data were collected between 5 January and 1 February 2021. For collecting data from
mainland Chinese university students, Sojump was used to host an online survey, and the
data were collected between 5 January and 16 January 2021. More specifically, the link
and Quick Response (QR) code of the Google Forms survey was sent out to the Taiwanese
university students with assistance from university faculty members; the Sojump survey
was sent out to mainland Chinese university students with assistance from university
counselors. A total of 761 Taiwanese university students and 3145 mainland Chinese
students participated in the present study.
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The inclusion criteria for the present study’s participants were (i) currently enrolled at
university and studying an undergraduate or postgraduate program and (ii) being aged
20 years or above (for Taiwanese students) or 18 years or above (for mainland Chinese
students). The difference in ages was due to the Taiwan IRB requesting that Taiwanese
students aged under 20 years needed to have parental consent to participate. The study
information was clearly and thoroughly described at the beginning of the online survey,
and only those who agreed to provide informed consent were able to participate in the
survey. Moreover, the online surveys could not be submitted if any questions were left
blank. Therefore, the present study had no missing data in either the Taiwanese and
mainland Chinese samples.
2.2. The DrVac-COVID19S and Demographic Questionnaire
The DrVac-COVID19S (Appendix A) was adapted from the MoVac-Flu Scale with
permission from Professor Vallée-Tourangeau, the developer of the MoVac-Flu Scale. The
major difference between the DrVac-COVID19S and the MoVac-Flu Scale is that the MoVac-
Flu Scale uses the word flu, and the DrVac-COVID19S uses the word COVID-19. The
DrVac-COVID19S contains 12 items, where nine items are positively worded (items 1 to 6,
8, 9, and 12) and three items are negatively worded (items 7, 10, and 11). Therefore, the
DrVac-COVID19S shares the same model of CME as the MoVac-Flu Scale in assessing an
individual’s values, impacts, knowledge, and autonomy traits. The four traits can help
healthcare providers and researchers to understand how an individual (i) cares about the
purpose of COVID-19 vaccination uptake (values); (ii) believes in the effects of COVID-
19 vaccination uptake in preventing COVID-19 infection (impacts); (iii) has knowledge
regarding the COVID-19 vaccination uptake (knowledge); and (iv) is confident and has
control in getting COVID-19 vaccination if the individual wants to (autonomy). Moreover,
the 12 items comprise four traits corresponding to the CME model: items 3 (“It is important
that I get the COVID-19 jab”), 6 (“The COVID-19 jab plays an important role in protecting
my life and that of others”), and 8 (“The contribution of the COVID-19 jab to my health and
well-being is very important”) comprise values; items 1 (“Vaccination is a very effective
way to protect me against the COVID-19”), 4 (“Vaccination greatly reduces my risk of
catching COVID-19), and 12 (“Getting the COVID-19 jab has a positive influence on my
health”) comprise impacts; items 2 (“I know very well how vaccination protects me from
the COVID-19”), 5 (“I understand how the flu jab helps my body fight the COVID-19
virus”), and 10 (“How the COVID-19 jab works to protect my health is a mystery to me”)
comprise knowledge; and items 7 (“I feel under pressure to get the COVID-19 jab”), 9 (“I
can choose whether to get a COVID-19 jab or not”), and 11 (“I get the COVID-19 jab only
because I am required to do so”) comprise autonomy. All the items are rated using a
seven-point Likert scale. After reverse coding, the negatively worded items (i.e., scoring
for these items are from 1 (strongly agree) to 7 (strongly disagree)), a higher score in the
DrVac-COVID19S indicates a higher level of COVID-19 vaccine acceptance.
The demographic questionnaire asked the participants’ sex (male or female), age (in
years), educational level (undergraduate or postgraduate), and their major subject of study.
2.3. Data Analysis
Descriptive statistics, including means and frequencies, were firstly used to exam-
ine the participants’ characteristics and the participants’ scores on the DrVac-COVID19S.
Moreover, χ2 test and independent t-test were used to examine differences in participant
characteristics and the DrVac-COVID19S item score differences between Taiwanese and
mainland Chinese university students. The present study tested four-factor structures for
the DrVac-COVID19S, including the nine-item one-trait-factor structure (using nine posi-
tively worded items), nine-item four-trait-factor structure (using nine positively worded
items), 12-item one-trait-factor with two-minus-one-method-factor structure (method factor
constructed on negatively worded items), and 12-item four-trait-factor with two-minus-
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one-method factor structure (method factor constructed on negatively worded items) (see
Figure 1).
Vaccines 2021, 9, x  5 of 19 
 
 
the DrVac-COVID19S, including the nine-item one-trait-factor structure (using nine posi-
tively worded items), nine-item four-trait-factor structure (using nine positively worded 
items), 12-item one-trait-factor with two-minus-one-method-factor structure (method fac-
tor constructed on negatively worded items), and 12-item four-trait-factor with two-mi-
nus-one-method factor structure (method factor constructed on negatively worded items) 
(see Figure 1). 
    
Figure 1. The four confirmatory factor analysis models for the Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-
COVID19S) tested in the present study. (a) One-trait-factor model using 9 positively worded items; (b) Four-trait-factor 
model using 9 positively worded items; (c) One-trait-factor and two-minus-one-method-factor model using all 12 items; 
(d) Four-trait-factor and two-minus-one-method-factor model using all 12 items. Note: error terms are not presented in 
the figure. DrVac = DrVac-COVID19S; Know = knowledge; Aut = autonomy; Word = negative wording effect. 
The four-factor structures were evaluated using CFA. Moreover, the four trait factors 
are the four traits described in the CME model (i.e., value, impact, knowledge, and auton-
omy). The two-minus-one-method-factor structure was tested because the four-trait-fac-
tor with a two-method-factor structure is more complicated and usually has problems in 
convergence due to the violation of the parsimony principle for a CFA model [36]. 
All the CFA models were examined using the commonly used fit indices of compar-
ative fit index (CFI), Tucker–Lewis index (TLI), root mean square error of approximation 
(RMSEA), and standardized root mean squared residual (SRMR). A supported model 
should have CFI and TLI > 0.95 with RMSEA and SRMR < 0.08 [37,38]. More specifically, 
the CFI and TLI indicate to what extent the proposed model is better than the worst model 
(i.e., the null model in the CFA). Therefore, high values for CFI and TLI are expected. The 
RMSEA indicates whether the model fulfills the parsimony in the psychometric testing 
and a smaller value indicates more parsimony of the proposed model. The SRMR indi-
cates the residuals in the proposed model and, therefore, a small value is expected. Alt-
hough a non-significant χ2 also indicates a supported model, the χ2 test was not applied 
due to its sensitivity to large sample sizes [39]. Aside from the CFI, TLI, RMSEA, and 
SRMR, the four models were compared using χ2 difference tests to understand which fac-
tor structure significantly outperformed the others [40]. More specifically, when the χ2 
difference test is significant, the model with a lower value of χ2 is significantly better. All 
the CFAs were analyzed using the diagonally weighted least square estimator. 
Figure 1. The four confirmatory factor analysis models for the Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-
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figure. DrVac = DrVac-COVID19S; Know = knowledge; Aut = autonomy; Word = negative wording effect.
The four-factor structures were evaluated using CFA. Moreover, the four trait factors
are the four traits described in the CME model (i.e., value, impact, knowledge, and auton-
omy). The two-minus-one-method-factor structure was tested because the four-trait-factor
with a two-method-factor structure is more complicated and usually has problems in
convergence due to the violation of the parsimony principle for a CFA model [36].
All the CFA models were examined using the commonly used fit indices of compara-
tive fit index (CFI), Tucker–Lewis index (TLI), root mean square error of approxi ation
(RMSEA), and standardized root mean squared residual (SRMR). A supported model
should have CFI and TLI > 0.95 with RMSEA and SRMR < 0.08 [37,38]. More specifically,
the CFI and TLI indicate to what extent the proposed model is better than the worst model
(i.e., the null model in the CFA). Therefore, high values for CFI and TLI are expected. The
RMSEA indicates whether the model fulfills the parsimony in the psychometric testing
and a smaller value indicates more parsimony of the proposed model. The SRMR indicates
the residuals in the proposed odel and, therefore, a small value is expected. Although
a non-significant χ2 also indicates a supported model, the χ2 test was not applied due to
its sensitivity to large sample sizes [39]. Aside from the CFI, TLI, RMSEA, and SRMR, the
four models were compared using χ2 difference tests to understand which factor structure
significantly outperformed the others [40]. More specifically, when the χ2 difference test is
significant, the model with a lower value of χ2 is significantly better. All the CFAs were
analyzed using the diagonally weighted least square estimator.
Measurement invariance of the four-factor structures was separately examined for the
following subsamples: Taiwanese vs. mainland Chinese; males vs. females; and health-
related major students vs. non-health-related major students. With the test of measurement
invariance, it can be confirmed whether the factor structure of the DrVac-COVID19 was
interpreted in the same way across these subsamples. This further strengthens the evidence
regarding the DrVac-COVID19S’s factor structure. Three tests of measurement invariance
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were performed. For each test of measurement invariance, three nested models were
constructed: (i) a configural model, which freely estimated all the factor loadings and
item intercepts across the two subsamples (e.g., Taiwanese and mainland Chinese); (ii) a
factor-loading-constrained model, which constrained the factor loadings equally between
the two subsamples and freely estimated the item intercepts across the two subsamples;
and (iii) a factor-loading and item-intercept-constrained model, which constrained the
factor loadings and item intercepts equally between the two subsamples [38,41,42]. The
aforementioned CFI, TLI, RMSEA, and SRMR were used to examine whether a configural
model was supported. Moreover, ∆CFI, ∆RMSEA, and ∆SRMR were used to examine
whether the more constrained model was equivalent to the less constrained model. That
is, the configural model (a less constrained model) was compared with the factor-loading-
constrained model (a more constrained model), and the factor-loading-constrained model
(a less constrained model) was compared with the factor-loading and item-intercept-
constrained model (a more constrained model). ∆CFI > −0.01, ∆RMSEA < 0.015, and
∆SRMR < 0.03 (for factor loading) or < 0.01 (for item intercept) indicate that the two
nested models are equivalent and therefore the measurement invariance across the two
subsamples is supported for the tested factor model [43]. More specifically, when the values
fulfill the aforementioned cutoffs, this indicates that the two compared models are equally
good. IBM SPSS 24.0 (IBM Corp., Armonk, NY, USA) and LISREL (Scientific Software
International, Lincolnwood, IL, USA) were used for data analysis.
3. Results
The participants’ characteristics are presented in Table 1. These showed that 761 Tai-
wanese university students (483 (63.5%) females; mean (SD) age = 25.51 years (6.42) years) and
3145 mainland Chinese university students (1493 (50.2%) females; mean (SD) age = 20.72 years
(2.06)) participated in the present study. Most of the participants were studying in an under-
graduate program (458 (60.2%) Taiwanese and 3026 (96.2%) mainland Chinese) and studying
in a non-health-related program (286 (37.6%) Taiwanese and 241 (7.7%) mainland Chinese).
All these characteristics were significantly different between Taiwanese and mainland Chinese
students. Moreover, all the DrVac-COVID19S item scores, except for item 7, were significantly
different between Taiwanese and mainland Chinese students: Taiwanese students had signifi-
cantly higher scores in items 9 to 11, and mainland Chinese students had significantly higher
scores in items 1 to 6, 8, and 12.
The CFA results showed that the four proposed factor structures were relatively
good across all the subsamples (including Taiwanese vs. mainland Chinese, males vs.
females, and students majoring in health-related programs vs. those majoring in non-
health-related programs), except for slightly high RMSEAs (0.099 in nine-item one-trait-
factor structure for Taiwanese and 0.090 in students majoring in health-related programs;
0.107 in 12-item one-trait-factor and two-minus-one-method- factor structure for Taiwanese
and 0.095 in students majoring in health-related programs). Moreover, the χ2 difference
tests demonstrated that the nine-item four-trait-factor model significantly fitted better
than the nine-item one-trait-factor model (p < 0.001); the 12-item four-trait-factor and
two-minus-one-method-factor model significantly fitted better than the 12-item one-trait-
factor and two-minus-one-method-factor model (p < 0.001). Therefore, four-trait-factor
models appeared to outperform one-trait-factor models irrespective of item numbers for
the DrVac-COVID19S (Table 2).
Measurement invariance was subsequently carried to understand which factor struc-
ture(s) was (were) invariant across subsamples (Table 3). All the configural models had
excellent fit indices (CFI = 0.984 to 0.998; RMSEA = 0.043 to 0.076; SRMR = 0.018 to
0.047) for all the factor structure models in all the subsamples. Most of the fit indices
in measurement invariance testing supported that the four-factor structures (including
nine-item one-trait-factor model, nine-item four-trait-factor model, 12-item one-trait-factor
and two-minus-one-method-factor model, and 12-item four-trait-factor and two-minus-
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one-method-factor model) were invariant across regions (Taiwan vs. mainland China), sex
(male vs. female), and study majors (health-related vs. non-health-related).
Table 1. Participants’ characteristics and item score in the Drivers of COVID-19 Vaccination Acceptance Scale
(DrVac-COVID19S).
Variables






Sex (female) 483 (63.5%) 1493 (50.2%) 43.45 (<0.01)
Age 25.51 (6.42) 20.72 (2.06) 19.58 (<0.01)
Education level (undergraduate) 458 (60.2%) 3026 (96.2%) 847.54 (<0.01)
Education (health-related) 286 (37.6%) 241 (7.7%) 469.94 (<0.01)
DrVac-COVID19S
Item 1 5.08 (1.24) 5.76 (1.16) 14.29 (<0.01)
Item 2 4.86 (1.43) 5.62 (1.24) 13.35 (<0.01)
Item 3 5.19 (1.44) 5.93 (1.14) 13.21 (<0.01)
Item 4 5.18 (1.35) 5.94 (1.08) 14.38 (<0.01)
Item 5 4.91 (1.52) 5.62 (1.28) 11.87 (<0.01)
Item 6 5.40 (1.31) 6.00 (1.06) 11.75 (<0.01)
Item 7 a 4.89 (1.39) 4.85 (1.61) 0.68 (0.50)
Item 8 5.23 (1.29) 5.88 (1.14) 12.76 (<0.01)
Item 9 5.92 (1.06) 5.78 (1.24) 3.27 (<0.01)
Item 10 a 5.20 (1.40) 4.78 (1.65) 7.09 (<0.01)
Item 11 a 4.62 (1.54) 4.43 (1.77) 2.95 (<0.01)
Item 12 5.09 (1.21) 5.42 (1.39) 6.58 (<0.01)
a Reverse-coded items (scoring for these items are from 1 (strongly agree) to 7 (strongly disagree)). Item 1: Vaccination is a very effective
way to protect me against COVID-19. Item 2: I know very well how vaccination protects me from COVID-19. Item 3: It is important that I
get the COVID-19 jab. Item 4: Vaccination greatly reduces my risk of catching COVID-19. Item 5: I understand how the flu jab helps my
body fight the COVID-19 virus. Item 6: The COVID-19 jab plays an important role in protecting my life and that of others. Item 7: I feel
under pressure to get the COVID-19 jab. Item 8: The contribution of the COVID-19 jab to my health and well-being is very important.
Item 9: I can choose whether to get a COVID-19 jab or not. Item 10: How the COVID-19 jab works to protect my health is a mystery to
me. Item 11: I get the COVID-19 jab only because I am required to do so. Item 12: Getting the COVID-19 jab has a positive influence on
my health.
Table 2. Confirmatory factor analysis results of the Drivers of COVID-19 Vaccination Acceptance Scale (DrVac-COVID19S)
in different subsamples.
Subsample Nine-Item DrVac-COVID19S 12-Item DrVac-COVID19S
Fit Indices One-Factor Four-Factor One-Factor a Four-Factor a
Taiwan
χ2 (df )/p-value 212.59 (25)/<0.001 42.91 (20)/0.002 472.70 (49)/<0.001 195.52 (43)/<0.001
CFI 0.984 0.998 0.968 0.989
TLI 0.977 0.997 0.957 0.982
RMSEA 0.099 0.039 0.107 0.068
SRMR 0.051 0.016 0.063 0.048
Mainland China
χ2 (df )/p-value 269.73 (25)/<0.001 163.21 (20)/<0.001 702.93 (49)/<0.001 578.78 (43)/<0.001
CFI 0.995 0.997 0.989 0.991
TLI 0.993 0.995 0.985 0.986
RMSEA 0.056 0.048 0.065 0.063
SRMR 0.026 0.021 0.043 0.040
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Table 2. Cont.
Subsample Nine-Item DrVac-COVID19S 12-Item DrVac-COVID19S
Fit Indices One-Factor Four-Factor One-Factor a Four-Factor a
Male
χ2 (df )/p-value 204.47 (25)/<0.001 116.46 (20)/<0.001 561.18. (49)/<0.001 459.02(43)/<0.001
CFI 0.994 0.997 0.986 0.989
TLI 0.992 0.994 0.981 0.983
RMSEA 0.062 0.051 0.075 0.072
SRMR 0.029 0.022 0.047 0.044
Female
χ2 (df )/p-value 267.78 (25)/<0.001 83.64 (20)/<0.001 593.97 (49)/<0.001 339.13 (43)/<0.001
CFI 0.992 0.998 0.984 0.991
TLI 0.989 0.996 0.979 0.987
RMSEA 0.069 0.039 0.073 0.058
SRMR 0.029 0.017 0.047 0.041
Health major
χ2 (df )/p-value 130.44 (25)/<0.001 23.49 (20)/0.27 279.40 (49)/<0.001 122.65 (43)/<0.001
CFI 0.988 0.999 0.976 0.992
TLI 0.983 0.999 0.968 0.988
RMSEA 0.090 0.018 0.095 0.059
SRMR 0.036 0.016 0.055 0.046
Non-health major
χ2 (df )/p-value 331.28 (25)/<0.001 154.55 (20)/<0.001 882.10 (49)/<0.001 661.03 (43)/<0.001
CFI 0.994 0.997 0.986 0.990
TLI 0.992 0.995 0.982 0.985
RMSEA 0.060 0.045 0.071 0.065
SRMR 0.028 0.020 0.047 0.043
Table 3. Measurement invariance testing across subsamples in the structure of the Drivers of COVID-19 Vaccination
Acceptance Scale (DrVac-COVID19S).
Model (Subsamples) Nine-Item DrVac-COVID19S 12-Item DrVac-COVID19S
Fit Indices One-Factor Four-Factor One-Factor a Four-Factor a
Configural (Taiwan vs. China)
χ2 (df )/p-value 482.57 (50)/<0.001 207.81(40)/<0.001 1171.60 (98)/<0.001 771.18 (86)/<0.001
CFI 0.993 0.997 0.984 0.990
RMSEA 0.067 0.046 0.075 0.064
SRMR 0.026 0.021 0.042 0.039
Loading constrained (Taiwan vs. China)
∆χ2 (df )/p-value 153.75 (8)/<0.001 32.55 (5)/<0.001 207.93 (13)/<0.001 182.24 (15)/<0.001
∆CFI −0.002 0.000 −0.003 −0.002
∆RMSEA 0.004 0.001 0.002 0.002
∆SRMR 0.008 0.003 0.006 0.004
Loadings and intercepts constrained (Taiwan vs. China)
∆χ2 (df )/p-value 198.23 (8)/<0.001 500.43 (5)/<0.001 252.63 (10)/<0.001 143.47 (7)/<0.001
∆CFI −0.004 −0.030 −0.002 −0.002
∆RMSEA 0.006 0.037 0.003 0.002
∆SRMR 0.009 −0.008 0.011 0.043
Configural (male vs. female)
χ2 (df )/p-value 466.72(50)/<0.001 201.80 (40)/<0.001 1152.51(98)/<0.001 806.23 (86)/<0.001
CFI 0.994 0.997 0.986 0.991
RMSEA 0.065 0.046 0.074 0.066
SRMR 0.029 0.018 0.047 0.041
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Table 3. Cont.
Model (Subsamples) Nine-Item DrVac-COVID19S 12-Item DrVac-COVID19S
Fit Indices One-Factor Four-Factor One-Factor a Four-Factor a
Loading constrained (male vs. female)
∆χ2 (df )/p-value 55.59 (8)/<0.001 23.07 (5)/<0.001 117.06 (13)/<0.001 109.59 (15)/<0.001
∆CFI −0.001 0.000 −0.001 −0.001
∆RMSEA −0.001 −0.001 −0.001 −0.002
∆SRMR 0.007 0.003 0.026 0.027
Loadings and intercepts constrained (male vs. female)
∆χ2 (df )/p-value 236.36 (8)/<0.001 186.10 (5)/<0.001 143.41 (10)/<0.001 63.20 (7)/<0.001
∆CFI −0.018 −0.010 −0.003 −0.002
∆RMSEA 0.009 0.016 0.001 0.000
∆SRMR −0.023 −0.015 −0.010 −0.021
Configural (health vs. non-health)
χ2 (df )/p-value 476.22 (50)/<0.001 186.48 (40)/<0.001 1189.99 (98)/<0.001 803.93 (86)/<0.001
CFI 0.994 0.998 0.985 0.990
RMSEA 0.066 0.043 0.076 0.065
SRMR 0.028 0.020 0.047 0.043
Loading constrained (health vs. non-health)
∆χ2 (df )/p-value 60.75 (8)/<0.001 21.24 (5)/<0.001 97.28 (13)/<0.001 116.93 (15)/<0.001
∆CFI −0.001 0.000 −0.001 −0.001
∆RMSEA −0.001 0.000 −0.002 −0.001
∆SRMR 0.001 0.001 0.001 0.001
Loadings and intercepts constrained (health vs. non-health)
∆χ2 (df )/p-value 105.16 (8)/<0.001 388.86 (5)/<0.001 165.84 (10)/<0.001 72.71 (7)/<0.001
∆CFI −0.002 −0.026 −0.003 −0.001
∆RMSEA 0.002 0.032 0.001 0.001
∆SRMR 0.003 −0.013 0.005 0.025
CFI = comparative fit index; TLI = Tucker–Lewis index; RMSEA = root mean square error of approximation; SRMR = standardized root
mean square residual. Excellent fit values are in bold; i.e., CFI and TLI > 0.95; RMSEA and SRMR < 0.08. Supported measurement
invariance values are in bold; i.e., ∆CFI > −0.01; ∆RMSEA < 0.015; ∆SRMR < 0.03 (for factor loading) or < 0.01 (for item intercept). a Using
correlated trait correlated method minus one model to control wording effects.
4. Discussion
The present study replicated the findings of the DrVac-COVID19S factor structure in a
previous study [31]. More specifically, the DrVac-COVIDS19S corresponded well with the
four-trait-factor portrayed by the CME [29,30] (i.e., that values, impacts, knowledge, and
autonomy are important traits in explaining an individual’s underlying drivers to accept
COVID-19 vaccination). Similar to prior findings on the factor structure of the DrVac-
COVID19S [31], the present study found that the 12-item version of DrVac-COVID19S
should be controlled for its wording effects when evaluating its factor structure. Moreover,
the present study found that the four-trait-factor for the nine-item DrVac-COVID19S and
the four-trait-factor and two-minus-one-method factor for the 12-item DrVac-COVID19S
were supported consistently across different subsamples in the present study. Therefore,
the trait-factor structure of the DrVac-COVID19S (either nine-item or 12-item version) can
tentatively be concluded to be a four-trait-factor structure corresponding to the CME.
Although the present study’s findings agreed with the prior findings on the DrVac-
COVID19S factor structure [31], prior psychometric evidence concerning the MoVac-Flu
Scale (i.e., the instrument that was used and adapted to develop the DrVac-COVID19S)
supports a single trait-factor [29]. The different findings in the factor structures are likely
due to the different statistical methods used between the studies. More specifically, the
factor structure of the MoVac-Flu Scale was tested using exploratory factor analysis, and
the DrVac-COVID19S was tested using CFA [31]. Exploratory factor analysis cannot test
the factor structure via a hypothesized model, and it is subjective and arbitrary to decide
the number of factors in the structure. In contrast, CFA examines whether a factor structure
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fits well with a hypothesized model (e.g., the present study proposed a four-trait-factor
structure). Therefore, different findings may be obtained between exploratory factor
analysis and CFA. Nevertheless, the CFA findings in the present study and the previous
DrVac-COVID19S study [31] demonstrated acceptable fit indices for the one-trait-factor
structure of the DrVac-COVID19S. This implies that the DrVac-COVID19S fits well in
two types of trait-factor structures (i.e., one trait-factor and four trait-factors) [30]. More
specifically, the single trait in the one-trait-factor structure is the empowerment trait that is
constructed by values, impacts, knowledge, and autonomy. The traits in the four-trait-factor
structure are values, impacts, knowledge, and autonomy.
The four-trait-factor structure of the DrVac-COVID19S was further found to be equiv-
alent (or invariant) across three different subsamples (i.e., Taiwanese vs. mainland Chinese,
males vs. females, and health-related majors vs. non-health-related majors). These findings
indicate that the DrVac-COVID19S has a consistent factor structure and is interpreted
similarly across different subsamples. Given the robust findings, healthcare providers,
researchers, and policymakers can use the DrVac-COVID19S to better understand the
differences of willingness to uptake COVID-19 vaccination between subsamples. In other
words, the present study’s results demonstrate there are meaningful comparisons between
subsamples in the DrVac-COVID19S assessed willingness to uptake COVID-19 vaccination.
Based on the supported measurement invariance, the aforementioned stakeholder groups
can confidently use the DrVac-COVID19S to compare acceptance of COVID-19 vaccination
uptake between the subsampled groups (i.e., Taiwanese vs. mainland Chinese, males vs.
females, and health-related majors vs. non-health-related majors) and subsequently design
more effective programs to promote COVID-19 vaccination uptake.
With the development of the DrVac-COVID19S, researchers, healthcare providers,
and policymakers can further explore the underlying reasons regarding lower levels of
motivation to get COVID-19 vaccination. More specifically, using the four traits mentioned
in the CME, researchers, healthcare providers, and policymakers can examine whether an
individual’s low willingness to get vaccinated against COVID-19 is due to values, perceived
impacts, knowledge, autonomy, or any combination of the four traits. After obtaining such
information, appropriate policies or treatment programs can be developed to improve the
willingness to get vaccinated against COVID-19. For example, if an individual’s knowledge
is the reason for their low willingness to get vaccinated, education programs concerning
COVID-19 vaccination and methods to distribute such knowledge are potential ways to
improve the willingness to get vaccinated. Although some evidence has supported the
high willingness of COVID-19 vaccinating uptake across individuals in different countries
(e.g., [28,44–47]), some studies still reported low acceptance [48–51]. Therefore, increasing
the willingness of COVID-19 vaccination uptake among individuals is still necessary, and
this can be facilitated by using the DrVac-COVID19S for assessment to better understand
individuals’ attitudes. More specifically, the DrVac-COVID19S provides detailed informa-
tion regarding the underlying mechanisms as to why an individual is willing or unwilling
to get vaccinated against COVID-19. With such information, programs can be designed
to increase individuals’ willingness to get vaccinated. For example, the MoVac-Flu Scale
(i.e., the instrument on which the DrVac-COVID19S is based) has been used to explore and
understand the reasons why European healthcare workers accept flu vaccination [51].
There are some limitations to the present study. First, the present study only recruited
university students of a relatively young age (25.51 years among Taiwanese participants
and 20.72 among mainland Chinese participants). Therefore, the psychometric findings
from the present study cannot be generalized to a population other than young adults and
not to children, adolescents, middle-aged, and older adults. Following this limitation, the
response rate of the present study was unknown, given that individuals were invited to
participate via snowball sampling. Therefore, the present study’s findings may be biased
due to this recruitment method. Second, the present study’s participants were recruited
from Taiwan and mainland China, and the generalizability of the present findings cannot
be applied to other Chinese-speaking populations residing in other countries (e.g., those
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that live in Hong Kong as well as some populations in Malaysia and Singapore). Similarly,
the present findings cannot be generalized to any populations in a Western country. Future
studies on other ethnic populations or citizens residing in different countries are needed
to increase the psychometric evidence concerning the DrVac-COVID19S. Third, other
psychometric properties of the DrVac-COVID19S were not examined in the present study.
For example, no external criteria were used to assess the concurrent validity, and no test-
retest reliability was examined. Therefore, future studies testing other properties of the
DrVac-COVID19S are needed for researchers, healthcare providers, and policymakers to
better understand the features of the DrVac-COVID19S. Such research would provide better
insights regarding how to use the DrVac-COVID19S.
5. Conclusions
The present study found that the DrVac-COVID19S is a practical and valid instrument
to quickly capture university students’ willingness to get COVID-19 vaccination. Moreover,
the DrVac-COVID19S corresponds to the four traits described in the CME, and that can
help researchers, healthcare providers, and policymakers to have some insights into uni-
versity students’ underlying reasons to get COVID-19 vaccination. Nevertheless, further
psychometric evidence on the DrVac-COVID19S is needed to provide a comprehensive
and thorough evaluation of this instrument and prompt its use in the critical period of
promoting the uptake of COVID-19 vaccination.
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Appendix A Drivers of COVID-19 Vaccination Acceptance Scale
English version (items underlined are reverse-coded items)








2. I know very well how vaccination protects me from COVID-19.




















































Neither disagree nor agree (4)
Slightly agree (5)
Agree (6)
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Strongly agree (7)
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